Department of Otolaryngology-Head and Neck Surgery, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York.
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, U.S.A.
Laryngoscope. 2020 Nov;130(11):2598-2606. doi: 10.1002/lary.28523. Epub 2020 Feb 29.
Programmed death-ligand 1 (PD-L1) is an immune checkpoint protein that may be a useful prognostic biomarker in nasopharyngeal cancer (NPC). The purpose of this systematic review and meta-analysis was to investigate the relationship between PD-L1 expression and survival in NPC.
PubMed, Cochrane, Embase, Scopus, and Web of Science were searched from inception to present. A predefined inclusion and exclusion criteria were used to select articles. Hazard ratios (HRs) and 95% confidence intervals (CIs) were pooled for overall survival (OS), disease-free survival (DFS), and disease metastasis-free survival (DMFS).
Eleven studies published from 2014 to 2018 were included, with 1,356 total participants. PD-L1 expression was not associated with OS (HR = 1.10, 95% CI: 0.79-1.55), DFS (HR = 1.66, 95% CI: 0.68-4.03), or DMFS (HR = 1.18, 95% CI: 0.44-3.20).
The prognostic role of PD-L1 in NPC remains unsubstantiated. Future research is needed. Laryngoscope, 130:2598-2606, 2020.
程序性死亡配体 1（PD-L1）是一种免疫检查点蛋白，可能是鼻咽癌（NPC）的一种有用的预后生物标志物。本系统评价和荟萃分析的目的是研究 PD-L1 表达与 NPC 患者生存之间的关系。
从创建到现在，我们在 PubMed、Cochrane、Embase、Scopus 和 Web of Science 上进行了搜索。使用预设的纳入和排除标准来选择文章。汇总了总生存（OS）、无病生存（DFS）和无疾病转移生存（DMFS）的危险比（HRs）和 95%置信区间（CIs）。
纳入了 2014 年至 2018 年发表的 11 项研究，共有 1356 名参与者。PD-L1 表达与 OS（HR = 1.10，95%CI：0.79-1.55）、DFS（HR = 1.66，95%CI：0.68-4.03）或 DMFS（HR = 1.18，95%CI：0.44-3.20）均无相关性。
PD-L1 在 NPC 中的预后作用仍未得到证实。需要进一步的研究。《喉镜》，130：2598-2606，2020 年。
